Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q1 2025 · 10-Q
Revenue$3.39M$3.39M−1.1% vs Q1 2024 Net Income-$1.14M-$1.14MN/M vs Q1 2024 EPS Diluted-$1.34-$1.34N/M vs Q1 2024 Gross Profit$1,306,000+8.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flow-$912,000N/M Free Cash Flowderived-$917,000N/M Margins · derivedGross margin38.5%+3.4 pt vs Q1 2024
Operating margin-34.6%+1.6 pt vs Q1 2024
Net margin-33.7%+7.7 pt vs Q1 2024
ended Jun 30, 2024 · filed Aug 8, 2024 · 39 d after period end